# US 2018/0021422 A1 · A vaccine for use against subclinical lawsonia infection in a pig

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021422 A1
- Document ID: US20180021422A1
- Status: Published application
- Kind: A1
- Application number: 15/546,353
- Filed: 2016-02-03
- Published: 2018-01-25
- Earliest claimed: 2015-02-04
- Assignees: Intervet Inc.
- Applicants: Intervet Inc.
- Inventors: Antonius Arnoldus Christiaan Jacobs
- Web page: https://patentgrep.com/patent/US20180021422A1

## CPC

- A61K 39/105: {Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter}
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/521: {inactivated (killed)}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention pertains to a vaccine comprising non live Lawsonia intracellularis antigen and a pharmaceutically acceptable carrier for use in a method to reduce in a pig the negative impact on average daily weight gain (ADWG) associated with subclinical infection with Lawsonia intracellularis, by systemic administration of the vaccine to the pig.

## Claims

### Claim 1

A method to reduce the negative impact on average daily weight gain (ADWG) associated with subclinical infection with Lawsonia intracellularis in a pig comprising the systemic administration of a vaccine comprising non live Lawsonia intracellularis antigen and a pharmaceutically acceptable carrier to the pig.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method is for reducing the negative impact on ADWG during a finishing period of the pig.

### Claim 3 (depends on 1)

The method of claim 1, wherein the method is also for the reduction of shedding of Lawsonia intracellularis bacteria by the pig as a result of the infection.

### Claim 4 (depends on 1)

The method of claim 1, wherein, the vaccine is administered only once.

### Claim 5 (depends on 1)

The method of claim 1, wherein the vaccine is administered when the pig is 3-10 days of age.

### Claim 6 (depends on 1)

The method of claim 1, wherein the non live Lawsonia intracellularis antigen comprises the carbohydrates that in live Lawsonia intracellularis bacteria are in association with the outer cell membrane of these bacteria.

### Claim 7 (depends on 1)

The method of claim 1, wherein the non live Lawsonia intracellularis antigen is antigen purified from a composition comprising killed Lawsonia intracellularis bacteria.

### Claim 8 (depends on 1)

The method of claim 1, wherein the non live Lawsonia intracellularis antigen is killed whole cell Lawsonia intracellularis.

### Claim at position 9

9-10. (canceled)